L. A. Garraway, H. R. Widlund, M. A. Rubin, G. Getz, A. J. Berger et al., Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma, Nature, vol.436, issue.7047, pp.117-122, 2005.

R. King, P. B. Googe, K. N. Weilbaecher, M. C. Mihm, and F. De, Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors, Am J Surg Pathol, vol.25, issue.1, pp.51-57, 2001.

Y. Cheli, M. Ohanna, R. Ballotti, and C. Bertolotto, Fifteen-year quest for microphthalmia-associated transcription factor target genes, Pigment Cell Melanoma Res, vol.23, issue.1, pp.27-40, 2010.

S. Ugurel, R. Houben, D. Schrama, H. Voigt, M. Zapatka et al., Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response, Clin Cancer Res, vol.13, issue.21, pp.6344-6350, 2007.

E. M. Van-allen, N. Wagle, A. Sucker, D. J. Treacy, C. M. Johanessesn et al., The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma, Cancer Discov, vol.4, issue.1, pp.94-109, 2014.

J. Muller, O. Krijgsman, J. Tsoi, L. Robert, W. Hugo et al., Low MITF/ AXL ratio predicts early resistance to multiple targeted drugs in melanoma, Nat Commun, vol.5, p.5712, 2014.

L. Beuret, F. E. Denoyelle, C. Bille, K. Busca, R. Picardo et al., Up-regulation of MET expression by alpha-melanocytestimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis, J Biol Chem, vol.282, issue.19, pp.14140-14147, 2007.

K. S. Hoek, N. C. Schlegel, P. Brafford, A. Sucker, S. Ugurel et al., Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature, Pigment Cell Res, vol.19, issue.4, pp.290-302, 2006.

D. Javelaud, V. I. Alexaki, M. J. Pierrat, K. S. Hoek, S. Dennler et al., GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells, Pigment Cell Melanoma Res, vol.24, issue.5, pp.932-943, 2011.

S. Carreira, J. Goodall, L. Denat, M. Rodriguez, P. Nuciforo et al., Mitf regulation of Dia1 controls melanoma proliferation and invasiveness, Genes Dev, vol.20, issue.24, pp.3426-3439, 2006.

M. R. Eccles, S. He, A. Ahn, L. J. Slobbe, A. R. Jeffs et al., MITF and PAX3 play distinct roles in melanoma cell migration; outline of a "genetic switch" theory involving MITF and PAX3 in proliferative and invasive phenotypes of melanoma, Front Oncol, vol.3, p.229, 2013.

M. Ohanna, S. Giuliano, C. Bonet, V. Imbert, V. Hofman et al., Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome, 2011.

, Genes Dev, vol.25, issue.12, pp.1245-1261

T. Strub, S. Giuliano, T. Ye, C. Bonet, C. Keime et al., Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma, Oncogene, vol.30, issue.20, pp.2319-2332, 2011.

F. S. Hodi, S. J. O'day, D. F. Mcdermott, R. W. Weber, J. A. Sosman et al., Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, vol.363, issue.8, pp.711-723, 2010.

R. S. Herbst, J. C. Soria, M. Kowanetz, G. D. Fine, O. Hamid et al., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, vol.515, issue.7528, pp.563-567, 2014.

L. L. Van-der-woude, M. Gorris, A. Halilovic, C. G. Figdor, and I. De-vries, Migrating into the tumor: a roadmap for T cells, Trends Cancer, vol.3, issue.11, pp.797-808, 2017.

S. Riesenberg, A. Groetchen, R. Siddaway, T. Bald, J. Reinhardt et al., MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment, Nat Commun, vol.6, p.8755, 2015.

A. K. Kamaraju, C. Bertolotto, and J. Chebath, Pax3 downregulation and shut-off of melanogenesis in melanoma B16/F10.9 by interleukin-6 receptor signaling, J Biol Chem, vol.277, issue.17, pp.15132-15141, 2002.

K. S. Smalley, R. Contractor, T. K. Nguyen, M. Xiao, R. Edwards et al., Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression, Cancer Res, vol.68, issue.14, pp.5743-5752, 2008.

S. Kobold, M. Merk, L. Hofer, P. Peters, R. Bucala et al., The macrophage migration inhibitory factor (MIF)-homologue D-dopachrome tautomerase is a therapeutic target in a murine melanoma model, Oncotarget, vol.5, issue.1, pp.103-107, 2014.

K. Meeth, J. X. Wang, G. Micevic, W. Damsky, and M. W. Bosenberg, The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations, Pigment Cell Melanoma Res, vol.29, issue.5, pp.590-597, 2016.

L. Larribere, C. Hilmi, M. Khaled, C. Gaggioli, K. Bille et al., The cleavage of microphthalmia-associated transcription factor, MITF, by caspases plays an essential role in melanocyte and melanoma cell apoptosis, Genes Dev, vol.19, issue.17, pp.1980-1985, 2005.

J. Bourseguin, C. Bonet, E. Renaud, C. Pandiani, M. Boncompagni et al., FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02424498

S. Kobold, J. Steffen, M. Chaloupka, S. Grassmann, J. Henkel et al., Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer, J Natl Cancer Inst, vol.107, issue.1, p.364, 2015.

J. Nakayama, X. C. Guan, M. Nakashima, T. Mashino, and Y. Hori, In vitro comparison between mouse B16 and human melanoma cell lines of the expression of ICAM-1 induced by cytokines and/or hyperthermia, J Dermatol, vol.24, issue.6, pp.351-360, 1997.

W. Peng, J. Q. Chen, C. Liu, S. Malu, C. Creasy et al., Loss of PTEN promotes resistance to T cell--mediated immunotherapy, Cancer Discov, vol.6, issue.2, pp.202-216, 2016.

C. Wellbrock, S. Rana, H. Paterson, H. Pickersgill, T. Brummelkamp et al., Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF, PLoS One, vol.3, issue.7, p.2734, 2008.

R. K. Pachynski, A. Scholz, J. Monnier, E. C. Butcher, and Z. Ba, Evaluation of tumor-infiltrating leukocyte subsets in a subcutaneous tumor model, J Vis Exp, vol.98, 2015.

V. G. Pillarisetty, The pancreatic cancer microenvironment: an immunologic battleground, Oncoimmunology, vol.3, issue.8, p.950171, 2014.

J. Mestas and C. C. Hughes, Of mice and not men: differences between mouse and human immunology, J Immunol, vol.172, issue.5, pp.2731-2738, 2004.

G. S. Campanella, B. D. Medoff, L. A. Manice, R. A. Colvin, and A. D. Luster, Development of a novel chemokine-mediated in vivo T cell recruitment assay, J Immunol Methods, vol.331, issue.1-2, pp.127-139, 2008.

Z. S. Chheda, R. K. Sharma, and J. Vr, Chemoattractant receptors BLT1 and CXCR3 regulate antitumor immunity by facilitating CD8+ T cell migration into tumors, vol.197, pp.2016-2026, 2016.

A. Martin-fontecha, L. L. Thomsen, S. Brett, C. Gerard, M. Lipp et al., Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming, Nat Immunol, vol.5, issue.12, pp.1260-1265, 2004.

U. Mrowietz, U. Schwenk, S. Maune, J. Bartels, M. Küpper et al., The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice, Br J Cancer, vol.79, issue.7-8, pp.1025-1031, 1999.

A. S. Payne and L. A. Cornelius, The role of chemokines in melanoma tumor growth and metastasis, J Invest Dermatol, vol.118, issue.6, pp.915-922, 2002.

P. Dhawan and A. Richmond, Role of CXCL1 in tumorigenesis of melanoma, J Leukoc Biol, vol.72, issue.1, pp.9-18, 2002.

J. Luan, R. Shattuck-brandt, H. Haghnegahdar, J. D. Owen, R. Strieter et al., Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression, J Leukoc Biol, vol.62, issue.5, pp.588-597, 1997.

T. Botton, A. Puissant, Y. Cheli, T. Tomic, S. Giuliano et al., Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth, Cell Death Differ, vol.18, issue.1, pp.109-121, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00551041

S. Aida, Y. Sonobe, H. Tanimura, N. Oikawa, M. Yuhki et al., MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor, Cancer Lett, vol.409, pp.116-124, 2017.

G. Pawelec, Immune correlates of clinical outcome in melanoma, Immunology, vol.153, issue.4, pp.415-422, 2018.